IRIS
GATTI, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.946
Totale 2.946
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.946
Totale 2.946
Salva come PNG Salva come JPEG
Città #
Genova 2.196
Genoa 298
Rapallo 266
Vado Ligure 184
Bordighera 2
Totale 2.946
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm 157
Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells 153
Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. 149
In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity 139
SDF1 controls pituitary cell proliferation through the activation of ERK1/2 and the Ca2+-dependent cytosolic tyrosine kinase, Pyk2. 136
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets 135
Adiponectin as Novel Regulator of Cell Proliferation in Human Glioblastoma 131
Endometrial stem cells and human reproductive failure 124
An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells. 122
Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of Phidianidine A as a new CXCR4 ligand exhibiting antagonist activity 121
Different Effects of Human Umbilical Cord Mesenchymal Stem Cells on Glioblastoma Stem Cells by Direct Cell Interaction or Via Released Soluble Factors 121
Glioblastoma cancer stem cells: response to epidermal growth factor receptor kinase inhibitors 120
Ruta graveolens L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation 120
Differential efficacy of SSTR1, 2 and 5 agonists in the inhibition of C6 glioma growth in nude mice 119
Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature 110
Different response of human glioma tumor-initiating cells to EGFR kinase inhibitors. 109
The chemokine SDF1/CXCL12: a novel autocrine/paracrine factor involved in pituitary adenoma development 108
Somatostatin receptor 1, 2 and 5 activation leads to C6 glioma growth arrest in vitro and in vivo: analysis of the intracellular pathways involved 104
Canine osteosarcoma cell lines contain stem-like cancer cells: Biological and pharmacological characterization 101
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation 99
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 98
Somatostatin and somatostatin receptors 1, 2 and 5 selective agonists inhibit C6 glioma cell growth in vitro and in vivo: Analysis of activated intracellular pathways 96
17{beta}-ESTRADIOL PROMOTES BREAST CANCER CELL PROLIFERATION INDUCING SDF-1-MEDIATED EGFR TRANSACTIVATION: REVERSAL BY GEFITINIB PRE-TREATMENT. 87
Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt 76
Somatostatin receptors 1, 2 and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro, via a PTPh-dependent inhibition of ERK1/2. 75
Identification of the hydantoin alkaloids parazoanthines as novel CXCR4 antagonists by computational and in vitro functional characterization 74
Ruolo della chemochina SDF1 nella proliferazione del carcinoma mammario: meccanismi intracellulari e approcci farmacologici 48
Totale 3.032
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.200
article - articoli 8.737
book - libri 0
conference - conferenze 160
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 303
Totale 18.400
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020645 0 0 0 0 75 90 107 53 76 124 100 20
2020/2021275 19 26 21 25 34 19 32 14 19 28 25 13
2021/2022351 11 31 18 39 18 26 26 78 20 20 16 48
2022/2023320 24 29 5 38 35 57 0 27 41 2 57 5
2023/2024228 9 17 4 31 9 65 27 8 13 9 7 29
2024/2025202 30 40 13 64 55 0 0 0 0 0 0 0
Totale 3.032